Abstract
Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that immune therapies could be an effective approach to battle colorectal cancers that carry a mismatch repair machinery deficient phenotype. It is expected that as our knowledge of the different mechanisms of immune-resistance grows, this therapeutic modality might soon be applicable to all patients. However, due to the continuous increase in the cost of oncological drugs, some treatment overheads may soon become prohibitive for many. In this review we will examine the current evidence related to this topic with the objective to provide the reader with concise but practical information about the potential role of immunotherapy in CRC.
Keywords: Colon cancer, lynch syndrome, microsatellite instability, PD-1 blockage, pembrolizumab.
Reviews on Recent Clinical Trials
Title:What is the Current Role of Immunotherapy for Colon Cancer?
Volume: 11 Issue: 2
Author(s): Fernando Galanternik, Gonzalo Recondo, Matías E. Valsecchi, Martín Greco, Gonzalo Recondo, Máximo de la Vega and E. Diaz Cantón
Affiliation:
Keywords: Colon cancer, lynch syndrome, microsatellite instability, PD-1 blockage, pembrolizumab.
Abstract: Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that immune therapies could be an effective approach to battle colorectal cancers that carry a mismatch repair machinery deficient phenotype. It is expected that as our knowledge of the different mechanisms of immune-resistance grows, this therapeutic modality might soon be applicable to all patients. However, due to the continuous increase in the cost of oncological drugs, some treatment overheads may soon become prohibitive for many. In this review we will examine the current evidence related to this topic with the objective to provide the reader with concise but practical information about the potential role of immunotherapy in CRC.
Export Options
About this article
Cite this article as:
Galanternik Fernando, Recondo Gonzalo, E. Valsecchi Matías, Greco Martín, Recondo Gonzalo, de la Vega Máximo and Diaz Cantón E., What is the Current Role of Immunotherapy for Colon Cancer?, Reviews on Recent Clinical Trials 2016; 11 (2) . https://dx.doi.org/10.2174/1574887111666160330121851
DOI https://dx.doi.org/10.2174/1574887111666160330121851 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Editorial [Hot Topic (2): Current Advances in Cancer Prevention and Treatment by Natural Products (Guest Editor: Anupam Bishayee, M.Pharm., Ph.D.)]
Current Pharmaceutical Biotechnology Vitamin D and the Epigenetic Machinery in Colon Cancer
Current Medicinal Chemistry Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Current Drug Targets Drug-Glycosidation and Drug Development
Mini-Reviews in Medicinal Chemistry Pharmacophore Generation and 3D-QSAR of Novel 2-(quinazolin-4- ylamino)-[1,4] Benzoquinone Derivatives as VEGFR-2 Inhibitors
Letters in Drug Design & Discovery Mesenchymal stem cell therapy for inflammatory bowel diseases: promise and challenge
Current Stem Cell Research & Therapy Association between Serum Vitamin D Level and Echocardiographic Abnormalities in Patients with Thalassemia Major
Cardiovascular & Hematological Disorders-Drug Targets Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery
Mini-Reviews in Medicinal Chemistry Natural Bioactive Compounds as Emerging Therapeutic Molecules Against Breast Cancer: Emphasis on the Role of Phytoestrogens
Current Drug Targets Application of In Vivo Animal Models to Characterize the Pharmacokinetic and Pharmacodynamic Properties of Drug Candidates in Discovery Settings
Combinatorial Chemistry & High Throughput Screening Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy Multiple Functions of Mammalian Germinal Center Kinases
Current Chemical Biology Nanoparticle-Based Combination Therapy for Cancer Treatment
Current Pharmaceutical Design